Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
SAN DIEGO, Nov. 07, 2016 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, announced today that Charles Theuer, M.D, Ph.D., President and CEO, will present at the following investor conferences in November:
Stifel 2016 Healthcare Conference
Tuesday, November 15, at 3:00 PM EST at the Lotte New York Palace Hotel in New York, NY
Jefferies 2016 London Healthcare Conference
Thursday, November 17, at 4:40 PM GMT (11:40 AM EST) at the Waldorf Hilton in London, UK
28th Annual Piper Jaffray Healthcare Conference
Wednesday, November 30, at 9:30 AM EST at the Lotte New York Palace Hotel in New York, NY
To access live webcasts of the presentations, please visit the “Events and Presentation” section within the “Investors” section of the TRACON Pharmaceuticals website at www.traconpharma.com. A replay of the webcasts will be available on the website for 60 days following the events.
About TRACON
TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. The Company is also developing two programs in-licensed from Janssen Pharmaceutica N.V. – TRC253, a small molecule inhibitor of wild type androgen receptor (AR) and multiple AR mutations that confer drug resistance, which is intended for the treatment of men with prostate cancer, and TRC694, a small molecule inhibitor of NF-kB inducing kinase (NIK), which is intended for the treatment of patients with hematologic malignancies, including myeloma. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
Company Contact: Casey Logan Chief Business Officer (858) 550‐0780 ext. 236 [email protected] Investor Contact: Andrew McDonald LifeSci Advisors LLC 646-597-6987 [email protected]
